Novartis hits targets in overdue-stage QMF149 bronchial asthma trial

697
0
Novartis has announced that a segment III QUARTZ looks at its investigational inhaled combination remedy; QMF149 has met number one and critical secondary endpoints in sufferers with inadequately managed bronchial ...
Load More